Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 ... SBWire (press release) Boston, MA -- (SBWIRE) -- 10/08/2013 -- Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of ... |
